Xylem Inc.
$25.89B- Market cap
- $24.88B
- Debt
- +$2.49B
- Cash
- −$1.48B
Capital structure 91% equity / 9% debt · EV / Revenue 2.87x · EV proxy / EBITDA proxy 14.40x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $24.88B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: XYL stock price at premium vs MRK $106.55 current versus $77.92 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MRK's multiple
Implied fair value · at XYL's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple discount
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 91% equity / 9% debt · EV / Revenue 2.87x · EV proxy / EBITDA proxy 14.40x
Capital structure 88% equity / 12% debt · EV / Revenue 6.03x
MRK carries the larger enterprise value at $391.80B against $25.89B; XYL trades on the lower EV / Revenue multiple (2.87x vs 6.03x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Xylem Inc. · implied price per share
Bear
$41.63
Base
$50.57
Bull
$62.62
Merck & Co., Inc. · implied price per share
Bear
$56.95
Base
$70.71
Bull
$89.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DANAHER CORP /DE/
XYL vs DHR
IDEX CORP /DE/
XYL vs IEX
PENTAIR plc
XYL vs PNR
ECOLAB INC.
XYL vs ECL
FLOWSERVE CORP
XYL vs FLS
DOVER Corp
XYL vs DOV
Pfizer Inc.
XYL vs PFE
Johnson & Johnson
XYL vs JNJ
Eli Lilly and Company
XYL vs LLY
Bristol-Myers Squibb Company
XYL vs BMY
AbbVie Inc.
XYL vs ABBV
AMGEN INC
XYL vs AMGN
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.